Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1

By afschroeder • June 11, 2026

Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1. JCEM Case Rep. 2026 Jun 9;4(7):luag112. doi: 10.1210/jcemcr/luag112. PMID: 42273283; PMCID: PMC13247532.

Tags: APS-1, autoimmune polyglandular syndrome type 1, diabetes mellitus, Digestive Diseases, Endocrinology, Fellow, Hematology/Oncology, Hepatitis, ICI, immune checkpoint inhibitor, immune-related adverse event, irae, Publications, thyroiditis

Comparative evaluation of bipolar versus monopolar energy platforms in G-POEM for gastroparesis: technical performance, learning curves, and clinical outcomes

Sarici IS, Khataniar H, Kolb JM, Eriksson SE, Newhams K, Albus K, Zheng P, Ayazi S. Comparative evaluation of bipolar versus monopolar energy platforms in[...]

Factors Associated With Food Allergy and Gut Microbiota Dysfunction

McCarthy WJ, Ferguson F, Jacobs JP. Factors Associated With Food Allergy and Gut Microbiota Dysfunction. JAMA Pediatr. 2026 Jun 8. doi: 10.1001/jamapediatrics.2026.2034. Epub ahead of[...]

Social determinants of health and sex differences: insights from NIH Specialized Centers of Research Excellence (SCORE)

A McKee S, Chang L, M Aris I. Social determinants of health and sex differences: insights from NIH Specialized Centers of Research Excellence (SCORE). Biol[...]